Table 1 |
||||||||||
|
Baseline characteristics of participants in the AMIS Study (Number = 4,352) |
||||||||||
|
Aspirin group |
Placebo group |
|||||||||
|
|
||||||||||
|
Quartile 1 |
Quartile 2 |
Quartile 3 |
Quartile 4 |
Total |
Quartile 1 |
Quartile 2 |
Quartile 3 |
Quartile 4 |
Total |
|
|
|
||||||||||
|
sUA range, mg/dL men |
2.5-4.5 |
4.52-5.37 |
5.38-6.45 |
6.47-10.45 |
2.50-10.45 |
2.38-4.48 |
4.5-5.42 |
5.47-6.48 |
6.52-11.05 |
2.38-11.05 |
|
women |
1.4-5.25 |
5.27-6.03 |
6.05-7 |
7.02-12.52 |
1.40-12.52 |
1.83-5.28 |
5.3-6.03 |
6.05-6.97 |
6.98-12.12 |
1.83-12.12 |
|
Number |
543 |
541 |
541 |
544 |
2,169 |
547 |
539 |
551 |
546 |
2,183 |
|
Mean sUA, mg/dL (SD) |
4.55 (0.57) |
5.55 (0.34) |
6.44 (0.34) |
8.05 (0.99) |
6.15 (1.43) |
4.59 (0.57) |
5.61 (0.3) |
6.43 (0.32) |
7.93 (0.91) |
6.14 (1.35) |
|
Demographics |
||||||||||
|
Age at first MI, years (SD) |
52.6 (8.0) |
52.5 (8.0) |
52.6 (8.3) |
52.8 (8.2) |
52.6 (8.1) |
53.0 (7.6) |
52.7 (8.1) |
52.5 (8.0) |
52.7 (7.9) |
52.7 (7.9) |
|
Age at most recent MI, years (SD) |
53.1 (7.8) |
53.1 (7.9) |
53.1 (8.3) |
53.5 (8.0) |
53.2 (8.0) |
53.5 (7.6) |
53.1 (8.0) |
52.9 (7.9) |
53.4 (7.8) |
53.2 (7.8) |
|
Age at randomization, years (SD) |
54.8 (8.0) |
54.8 (8.0) |
54.8 (8.4) |
55.1 (8.1) |
54.9 (8.1) |
55.2 (7.6) |
54.8 (8.1) |
54.5 (8.0) |
55.0 (7.9) |
54.9 (7.88) |
|
Body mass index, kg/m2 (SD) |
24.8 (3.2) |
25.6 (3.3) |
26.1 (3.2) |
27.1 (3.7) |
25.9 (3.5) |
25.1 (3.1) |
25.6 (3.2) |
26.4 (3.4) |
26.8 (3.8) |
26.0 (3.5) |
|
Men, % |
88.8 |
88.2 |
88.4 |
88.6 |
88.5 |
89.8 |
89.4 |
89.7 |
89.7 |
89.6 |
|
African American, % |
5.7 |
4.3 |
6.7 |
9 |
6.4 |
7.1 |
5.9 |
3.1 |
7.5 |
5.9 |
|
Physical examination data |
||||||||||
|
Sedentary lifestyle, % |
16.7 |
16.3 |
17.4 |
21.3 |
17.9 |
16.8 |
15.6 |
15.4 |
20.9 |
17.2 |
|
Alcohol usea, % |
88.4 |
84.7 |
82.1 |
82 |
84.3 |
88.1 |
84.6 |
85.3 |
80.6 |
84.7 |
|
Smokerb, % |
40.7 |
40.1 |
31.8 |
29.6 |
35.5 |
39.9 |
37.3 |
31.2 |
32.8 |
35.3 |
|
Heavy smokerc, % |
10.1 |
10.3 |
12.1 |
10 |
10.6 |
7.2 |
5.8 |
15.7 |
11.4 |
9.8 |
|
Systolic blood pressure, mmHg (SD) |
126.4 (15.6) |
126.1 (15.4) |
129.0 (16.6) |
129.6 (16.5) |
127.8 (16.1) |
127.5 (17.1) |
127.1 (15.1) |
128.5 (15.5) |
129.5 (16.9) |
128.2 (16.2) |
|
Diastolic blood pressure, mmHg (SD) |
78.3 (9.4) |
78.9 (8.9) |
79.6 (9.2) |
81.7 (9.8) |
79.6 (9.4) |
79.2 (9.3) |
78.9 (8.9) |
80.3 (9.4) |
81.9 (10.0) |
80.1 (9.5) |
|
Laboratory data |
||||||||||
|
Total glucose, mg/100 ml (SD) |
148.8 (56.8) |
155.4 (57.7) |
158.4 (50.1) |
171.2 (49.9) |
158.6 (54.3) |
159.1 (67.5) |
156.7 (53.3) |
160.1 (50.5) |
168.9 (52.2) |
161.2 (56.3) |
|
Total cholesterol, mg/dL (SD) |
230.4 (44.7) |
235.7 (43.3) |
240.4 (43.2) |
243.2 (49.0) |
237.7 (45.5) |
234.0 (43.2) |
235.1 (42.4) |
240.2 (41.8) |
241.2 (42.5) |
237.7 (42.5) |
|
Triglycerides, mg/dL (SD) |
160.7 (130.0) |
173.3 (101.6) |
190.6 (149.1) |
228.7 (192.2) |
189.9 (159.2) |
153.3 (86.2) |
162.7 (97.0) |
191.5 (116.6) |
230.1 (169.3) |
185.2 (125.7) |
|
Comorbidities, % |
||||||||||
|
Number of prior MI |
||||||||||
|
1 |
88.4 |
86.7 |
86.1 |
84.2 |
86.4 |
86.1 |
88.7 |
90.0 |
83.0 |
86.9 |
|
2 |
10.1 |
12.4 |
12.6 |
13.6 |
12.2 |
11.3 |
10.4 |
8.5 |
14.7 |
11.2 |
|
≥ 3 |
1.5 |
0.9 |
1.3 |
2.2 |
1.5 |
2.6 |
0.9 |
1.5 |
2.4 |
1.8 |
|
History of diabetes |
13.4 |
8.1 |
9.2 |
8.8 |
9.9 |
17 |
10.4 |
7.8 |
10.1 |
11.3 |
|
History of renal impairment |
4.2 |
4.6 |
5.2 |
6.6 |
5.2 |
3.7 |
4.3 |
4.9 |
6.8 |
4.9 |
|
Gout flaresd |
3.1 |
4.4 |
4.3 |
8.3 |
5.0 |
3.5 |
2.2 |
4.5 |
7.3 |
4.4 |
|
Medications, % |
||||||||||
|
Gout medicationsd, e |
4.2 |
4.1 |
3.1 |
5.0 |
4.1 |
3.3 |
2.0 |
4.5 |
4.8 |
3.7 |
|
Non-aspirin NSAIDs |
1.5 |
1.7 |
0.4 |
1.8 |
1.3 |
0.7 |
0.9 |
0.9 |
1.3 |
1.0 |
|
Anti-diabetic medications |
7.9 |
2.8 |
3.5 |
3.3 |
4.4 |
8.0 |
4.8 |
3.4 |
5.7 |
5.5 |
|
Blood pressure medications |
5.7 |
8.3 |
8.9 |
18.4 |
10.3 |
6.4 |
7.8 |
8.5 |
16.7 |
9.8 |
|
Lipid-lowering medications |
5.3 |
5.7 |
4.6 |
4.6 |
5.1 |
4.9 |
3.9 |
5.4 |
3.8 |
4.5 |
|
Follow-up time, years (SD)f |
2.9 (0.5) |
2.9 (0.5) |
2.8 (0.5) |
2.8 (0.5) |
2.8 (0.5) |
2.8 (0.5) |
2.8 (0.5) |
2.9 (0.5) |
2.8 (0.6) |
2.8 (0.5) |
|
Minimum (years) |
1.0 |
0.9 |
0.9 |
0.9 |
0.9 |
0.90 |
0.90 |
0.8 |
0.9 |
0.8 |
|
Maximum (years) |
3.2 |
3.2 |
3.2 |
3.2 |
3.2 |
3.2 |
3.2 |
3.2 |
3.1 |
3.2 |
|
|
||||||||||
|
a < 1.5 oz/day; bIncludes cigarettes, pipes, and cigars; c > 45 cigarettes/day; dGout flares and medications determined at baseline; eIncludes probenecid, allopurinol, and colchicine; fFollow up from baseline to last observation. Mean (standard deviation) is provided unless specified otherwise. AMIS, Aspirin Myocardial infarction study; MI, myocardial infarction; NSAID, non-steroidal anti-inflammatory drug; sUA, serum urate; SD, standard deviation. |
||||||||||
|
Krishnan et al. Arthritis Research & Therapy 2012 14:R10 doi:10.1186/ar3684 |
||||||||||
